The estimated Net Worth of Ronald R Taylor is at least $10.6 Million dollars as of 19 February 2021. Mr. Taylor owns over 4,000 units of Resmed stock worth over $4,683,992 and over the last 20 years he sold RMD stock worth over $5,575,694. In addition, he makes $345,052 as Lead Independent Director at Resmed.
Ronald has made over 10 trades of the Resmed stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 4,000 units of RMD stock worth $800,560 on 19 February 2021.
The largest trade he's ever made was exercising 84,000 units of Resmed stock on 24 February 2011 worth over $1,893,360. On average, Ronald trades about 3,700 units every 62 days since 2005. As of 19 February 2021 he still owns at least 18,769 units of Resmed stock.
You can see the complete history of Mr. Taylor stock trades at the bottom of the page.
Ronald R. Taylor serves as Lead Independent Director of the Company. Mr. Taylor founded Pyxis Corporation, a manufacturer of automated drug dispensers for hospitals, where he served as chair, president, and CEO until its purchase by Cardinal Health, Inc., in 1996. For six years before founding Pyxis, Mr. Taylor was responsible for operations and international sales at Hybritech, Inc., a biotechnology company. Before joining Hybritech, he served for 10 years in management roles at Allergan plc (NYSE: AGN), a pharmaceutical company. From 1998-2001, he was a general partner at Enterprise Partners Venture Capital. Mr. Taylor’s past public company board experience includes serving as a director at Allergan from 1994 through 2018. From 1998 through 2014, he served as a member of the Red Lion Hotels governance, compensation, and audit committees. From 2002 until his appointment to the ResMed board in 2005, he served as chair of the ResMed Foundation. Mr. Taylor has a bachelor of arts from the University of Saskatchewan and a master of arts from the University of California, Irvine. Mr. Taylor’s background reflects significant executive and operational experience with publicly-held medical technology and pharmaceutical companies, including experience in evaluating and investing in healthcare companies as a partner in a venture capital firm, and public company governance experience. He has been a director of approximately 20 publicly and privately held companies over the past 27 years. In addition, he has more than 15 years of experience as a member of the Red Lion Hotel’s governance, compensation and audit committees, and more than 20 years of experience as a member of the Allergan (formerly Watson and Actavis) audit, compensation and governance committees. Mr. Taylor’s experience and skills as a public medical technology company CEO, venture capital experience, and board experience, led the board to the conclusion that he should serve as a director.
As the Lead Independent Director of Resmed, the total compensation of Ronald Taylor at Resmed is $345,052. There are 14 executives at Resmed getting paid more, with Michael Farrell having the highest compensation of $10,429,800.
Ronald Taylor is 72, he's been the Lead Independent Director of Resmed since 2013. There are 3 older and 19 younger executives at Resmed. The oldest executive at Resmed Inc. is Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, 79, who is the Founder & Non-Exec. Chairman.
Ronald's mailing address filed with the SEC is 138 WEST CANOE POINT ROAD, , COOLIN, ID, 83821.
Over the last 22 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace, and David Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.
at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.
Resmed executives and other stock owners filed with the SEC include: